TearLab Corporation to Release Q2 2013 Financial Results on August 13, 2013
01 Août 2013 - 2:00AM
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its
Q2 2013 financial results after market closes on Tuesday, August
13, 2013.
TearLab is pleased to invite all willing participants in a
conference call during which time financial results will be
discussed. This call will be held at 4:30pm Eastern at
877-303-1593
Date: August 13, 2013 Time: 4:30 PM ET
Listen via Internet: http://www.tearlab.com/investor/
Schedule this webcast into MS-Outlook calendar (click open when
prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=60661&k=2FE3F26B
Telephone: 877-303-1593
For those wishing to listen to a recording of the call via
telephone, a replay will be made available by 7:30pm Eastern after
the conclusion of the live call and will remain posted until
11:59pm Eastern on August 20, 2013. To listen to the recording,
simply telephone 855-859-2056 (toll free) or 404-537-3406 and enter
conference ID: 27540820 when prompted.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and
commercializes lab-on-a-chip technologies that enable eye care
practitioners to improve standard of care by objectively and
quantitatively testing for disease markers in tears at the
point-of-care. The TearLab(r) Osmolarity Test, that enables eye
care practitioners to test for highly sensitive and specific
biomarkers using nanoliters of tear film at the point-of-care, is
the first assay developed for the award winning TearLab Osmolarity
System. Headquartered in San Diego, CA, TearLab Corporation's
common shares trade on the NASDAQ Capital Market under the symbol
'TEAR' and on the Toronto Stock Exchange under the symbol
'TLB'.
Forward-Looking Statements This press release may contain
forward-looking statements. These statements relate to future
events and are subject to risks, uncertainties and assumptions
about TearLab. Examples of forward-looking statements in this press
released include predictions regarding the sufficiency of current
cash and cash equivalents to fund operations, building sales in
Europe and Canada, improving third party reimbursement from
insurance companies, and the future commercial adoption of the
TearLab Osmolarity System. These statements are only predictions
based on our current expectations and projections about future
events. You should not place undue reliance on these statements.
Actual events or results may differ materially. Many factors may
cause our actual results to differ materially from any
forward-looking statement, including the factors detailed in our
filings with the Securities and Exchange Commission and Canadian
securities regulatory authorities, including but not limited to our
annual and quarterly reports on Forms 10-K and 10-Q. We do not
undertake to update any forward-looking statements.
CONTACT: Kilmer Lucas Inc.
Stephen Kilmer (President)
905 906-6908 Ext.21
stephen@kilmerlucas.com
Kilmer Lucas Inc.
Leonard Zehr (Managing Director)
905 690 2400 Ext.41
len@kilmerlucas.com
Talbots (NYSE:TLB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Talbots (NYSE:TLB)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
Real-Time news about Talbots (The) (New York Stock Exchange): 0 recent articles
Plus d'articles sur